Patent ID: 7947304

Claim:
A transdermal patch formulation comprising: hGH, wherein the hGH is present in an amount sufficient to achieve a formulation concentration of about 20 mg/ml to 255 mg/ml, sucrose, glycine, and phosphate buffer, wherein the phosphate buffer maintains the pH of the formulation in the range of about 6 to about 8, wherein the hGH, sucrose, and glycine are present in a concentration ratio (mg/ml) of about 0.85:0.80:0.26 to about 0.85:1.20:0.40, and wherein after six months of storage at a temperature of about 4° C. of a transdermal patch comprising the transdermal patch formulation in a dried form, the patch has deamidated, oxidated, cleaved and/or truncated hGH proteins in an amount of about 0.5% to about 13% of hGH and aggregate hGH proteins in an amount of about 0.01% to about 6% of hGH.